期刊
MYCOSES
卷 59, 期 1, 页码 39-42出版社
WILEY
DOI: 10.1111/myc.12432
关键词
Beta-1; 3-glucan; invasive fungal infection diagnostic test; antigen test; cell wall; Aspergillosis; candidemia
资金
- German Federal Ministry of Research and Education (BMBF) [01KN1106]
- European Commission
- 3M
- Actelion
- Astellas
- Basilea
- Bayer
- Cidara
- Cubist/Optimer
- Da Volterra
- Daiichi Sankyo
- F2G
- Genentech
- Genzyme
- Gilead
- GSK
- Medpace
- Merck Serono
- MSD
- Miltenyi
- NanoMR
- Novartis
- Parexel
- Pfizer
- Quintiles
- Rempex
- Roche
- Sanofi Pasteur
- Shionogi
- Summit/Vifor
- Viropharma
- Beckmann
- BioMerieux
- Bruker Daltonics
- Cepheid
- Hologic
- r-biopharm
- Siemens
1,3-ss-D-glucan (BDG) is increasingly used to diagnose invasive fungal infections (IFI), although false positive results are a concern. To evaluate the potential interaction of blood products with the BDG assay, human albumin (HA), fresh frozen plasma (FFP), undiluted platelet transfusion (UPT) and packed red blood cells (PRBC) were tested for their BDG content using two different b-D-glucan tests. UPTs tested negative, FFP, PBRC and HA tested positive for BDG. In serial dilution, BDG concentration correlated with blood product concentration. To investigate the clinical impact of blood product transfusions, we measured BDG levels before and after the transfusion in three patients (2 PRBC, 1 HA). In the patients receiving PRBC transfusions, BDG values increased from 13 and 17pgml(-1) to 183 and 361pgml(-1), the HA transfusion increased the serum level from 42 to 58pgml(-1). BDG concentrations measured in blood products can be used to predict false positive BDG results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据